Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 3/20 | 0.54 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.54 |
| ▸ | KDM1A | O60341 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12797772 | 0.83 | CYP3A4 (0.59) | HSD17B1HSD17B2KDM1AIDO1METAP2 | |
| SCHEMBL12973163 | 0.83 | HSD17B1 (0.59) | HSD17B1HSD17B2KDM1AIDO1METAP2 | |
| SCHEMBL18573279 | 0.83 | HSD17B1 (0.42) | HSD17B1HSD17B2KDM1AACHECYP3A4 | |
| SCHEMBL3422110 | 0.81 | IDO1 (0.58) | HSD17B1HSD17B2KDM1AIDO1METAP2 | |
| SCHEMBL4402515 | 0.80 | HSD17B1 (0.61) | HSD17B1HSD17B2KDM1AIDO1METAP2 | |
| SCHEMBL23572016 | 0.79 | HSD17B1 (0.69) | HSD17B1HSD17B2KDM1AMETAP2ACHE | |
| SCHEMBL14446367 | 0.79 | KDM1A (0.54) | HSD17B1HSD17B2KDM1AIDO1METAP2 | |
| SCHEMBL14988681 | 0.79 | KDM1A (0.61) | HSD17B1HSD17B2KDM1AIDO1METAP2 | |
| SCHEMBL30610289 | 0.79 | HSD17B1 (0.69) | HSD17B1HSD17B2KDM1AMETAP2ACHE | |
| SCHEMBL15014085 | 0.79 | KDM1A (0.54) | HSD17B1HSD17B2KDM1AIDO1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010485-B1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| EP-2010485-A1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | Prosidion Limited (GB) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007116230-A1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | GPR119, GPR39, GIPR | HSD17B1 2222/4885HSD17B2 2303/4885KDM1A 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.